Mesoblast (NASDAQ:MESO) has expanded its advanced therapy pipeline by acquiring an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform.
The clinical-stage biotechnology company secured the global rights through the acquisition of an early-stage startup, financing the transaction entirely through the issuance of Australian Securities Exchange (ASX) ordinary shares.
The newly acquired technology platform is designed to engineer chimeric antigen receptors directly into mesenchymal stromal cells (MSCs).
This cellular modification is a strategic operational step aimed at significantly enhancing the target specificity and overall therapeutic potency of Mesoblast's core cell therapy candidates.
The licensing agreement is uniquely fortified by a strategic institutional partnership, including comprehensive in-kind support and a Good Manufacturing Practice (GMP) collaboration with the Mayo Clinic.
This manufacturing alliance is expected to provide the critical clinical infrastructure required to accelerate the scale-up and advancement of CAR-MSC products into human trials.
Mesoblast intends to deploy this next-generation engineered cellular technology specifically for severe inflammatory and autoimmune indications.